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Background: A key issue for safe and reproducible gene therapy approaches is the autologous and tissue-specific
expression of transgenes. Tissue-specific expression in vivo is either achieved by transfer vectors that deliver the
gene of interest into a distinct cell type or by use of tissue-specific expression cassettes. Here we present the
generation of non-viral, episomally replicating vectors that are able to replicate in a tissue specific manner thus
allowing tissue specific transgene expression in combination with episomal replication. The episomal replication of
the prototype vector pEPI-1 and its derivatives depends exclusively on a transcription unit starting from a
constitutively active promoter extending into the scaffold/matrix attachment region (S/MAR).
Results: Here, we exchanged the constitutive promoter in the pEPI derivative pEPito by the tumor specific alpha
fetoprotein (AFP) or the muscle specific smooth muscle 22 (SM22) promoter leading to specific transgene expression in
AFP positive human hepatocellular carcinoma (HUH7) and in a SM22 positive cell line, respectively. The incorporation of
the hCMV enhancer element into the expression cassette further boosted the expression levels with both promoters.
Tissue specific-replication could be exemplary proven for the smooth muscle protein 22 (SM22) promoter in vitro. With
the AFP promoter-driven pEPito vector hepatocellular carcinoma-specific expression could be achieved in vivo after
systemic vector application together with polyethylenimine as transfection enhancer.
Conclusions: In this study we present an episomal plasmid system designed for tissue specific transgene expression
and replication. The human AFP-promoter in combination with the hCMV enhancer element was demonstrated to be
a valuable tissue-specific promoter for targeting hepatocellular carcinomas with non-viral gene delivery system, and
tissue specific replication could be shown in vitro with the muscle specific SM22 promoter. In combination with
appropriate delivery systems, the tissue specific pEPito vector system will allow higher tissue-specificity with less
undesired side effects and is suitable for long term transgene expression in vivo within gene therapeutical approaches.
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Sustained and tissue specific transgene expression are
key issues for the development of successful gene ther-
apy approaches. In principle, tissue specificity can be
achieved either by gene delivery systems which explicitly
deliver the gene of interest into a distinct cell type or tis-
sue [1] or by the use of tissue-specific expression
cassettes [2]. For sustained transgene expression, inte-
grating vectors, like viruses [3] or nonviral systems based* Correspondence: rudolf.haase@cup.uni-muenchen.de
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reproduction in any medium, provided the oron integrases or transposons have been utilized [4,5]. To
avoid the risk of insertional mutagenesis, as it has been
observed for example with retrovirus [6], nonintegrating
vectors like episomally retained systems can be of use.
The first prototype episomal vector pEPI-1 was cons-
tructed by Piechaczek and colleagues [7] carrying
a chromosomal scaffold/matrix attachment region
(S/MAR) derived from the β-interferon gene [8] within a
commercially available plasmid backbone; pEPI-1 is able
to replicate episomally with a copy number of approxi-
mately 5–10 molecules per cell and is stably retained
without applying selection pressure allowing long-term
expression of transgenes or shRNA’s [7,9-11]. Since inte-
gration of this vector into the host cell chromosome wastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Influence of the hCMV enhancer on liver promoter
mediated transfection in hepatocellular carcinoma cells. 50,000
HUH7 cells seeded in 24-well plates were transfected with HD-O
polyplexes containing the indicated plasmid (1.5 μg plasmid/well)
and the luciferase activity per 10,000 cells determined at indicated
time points; n = 2. Open symbols: CMV promoter; gray symbols: liver
promoter; full symbols: liver promoter plus hCMV enhancer.
Haase et al. BMC Biotechnology 2013, 13:49 Page 2 of 11
http://www.biomedcentral.com/1472-6750/13/49never observed, side effects caused by gene disruption or
activation would not be expected, but cannot be fully ex-
cluded. In contrast to episomal plasmid replicons based
on animal viruses, pEPI-based episomal DNA vectors do
not contain any transactivating viral proteins such as the
SV40 large T-antigen or the EBV EBNA-1 protein, which
may contribute to cellular immortalization [12]. An up-
stream transcription unit regulated by the CMV imme-
diate early promoter (CMV-IEP) and directed into the S/
MAR is necessary for episomal replication of pEPI
[10,13,14]. Our approach here was to modify this vector
system by exchanging the constitutive promoter with
tissue- or tumor-specific ones to generate a vector,
which will episomally express the transgene in the target
cell type only, but being lost in all other cell types. Re-
cently, similar effects with pEPI vectors utilizing chem-
ically inducible promoters could be shown [15].
Only a small percentage (between 0.5 and 5%) of cells
transiently transfected with pEPI-1 develops stable clones,
also when pEPI-1 plasmids are isolated from already
established cell clones and reintroduced into cells or if
pEPI-1 episomes are administered as HPV16 based
pseudoviral particles. This demonstrates that the primary
DNA sequence is not sufficient for stable establishment,
but other epigenetic factors are involved in this process
[14,16]. A further improvement of pEPI-1 concerning
transgene expression and episome establishment was pre-
viously published as pEPito [17]. pEPito consists of an
identical transcription unit as pEPI, but contains a CpG-
low vector backbone achieving higher expression levels
and episomal establishment rates compared to pEPI. Ini-
tially, the constitutive CMV or EF1α promoter was used
in pEPito vectors. In this study, we replaced them with tis-
sue specific promoters: i) the alpha fetoprotein (AFP) pro-
moter drives expression of AFP in the embryonic liver and
in hepatocellular carcinomas [18], ii) the SM22 promoter
has been described as tissue-specific promoter for smooth
muscle cells [19,20]. A tissue-specific AFP-dependent ex-
pressing pEPito derivate achieved liver carcinoma specific
expression in vitro and in vivo. For the SM22-promoter
driven pEPito derivative we present the tissue-specific rep-
lication of a S/MAR based vector in vitro. To cope with
the relatively low activity of tissue specific promoters, we
utilized the hCMV upstream of the AFP or SM22 pro-
moter. As the episomal maintainance of the pEPI-based
vectors are dependent on the transcription into the S/
MAR region [10], the replication of those vectors in cells
without any activity for the promoter should not occur.
Results
The AFP promoter is more active in HUH7 hepatocellular
carcinoma compared to HPGL promoter and APOE enhancer
Three liver specific promoters, alpha-fetoprotein pro-
moter (AFP), haptoglobin promoter (HPGL) and theapolipoprotein E enhancer (APO E) were evaluated for
their use as liver specific episomal vectors. The AFP and
HPGL promoters were obtained by PCR amplification of
genomic DNA obtained from HEK293 cells. Promoter
selection and primer choice were done under use of
TiProD. To enhance promoter activity, a human cyto-
megalovirus (hCMV) enhancer was cloned in front of
the promoter sequence. As depicted in Figure 1, all con-
structs featuring an hCMV enhancer element achieve
higher expression levels compared to the enhancer free
construct. The CMV driven vector pEPito-CMV-EGFPLuc
served as positive control achieving the highest lumines-
cence signal, followed by the hCMV/AFP-construct, the
hCMV/HPGL-construct and the much weaker respective
APOE-derivative. As expected, the APOE enhancer with-
out the hAAT promoter turned out to be inefficient for
driving transgene expression. Monitoring transgene ex-
pression over a period of 11 days exhibits decreasing ex-
pression signals over time, as no selection pressure was
put on the transfected cells. As the hCMV enhancer/AFP-
promoter combination achieved highest activity of all liver
specific promoter elements tested, it was selected for the
further experiments.
AFP promoter is most active in AFP-producing cell lines,
but also achieves weak expression levels in non-liver
derived cell lines
Plasmids pEPito-CMV-EGFPLuc, pEPito-AFP-EGFPLuc
and pEPito-hCMV/AFP-EGFPLuc were transfected into
13 different human and murine cancer cell lines (hepa-
toma, cervix carcinoma, colon carcinoma, glioma, prostate
carcinoma, melanoma, squamous cell carcinoma, neuro-
blastoma) and a murine fibroblast cell line (Figure 2).
In all cell lines transfected, the AFP plasmid without
Figure 2 Expression activity of CMV and AFP promoter driven
plasmids in human and murine cell lines. Indicated cell lines
were seeded in 96-well plates (10,000 cells/well seeded), transfected
with LPEI polyplexes (200 ng Plasmid/well) for four hours and the
luciferase activity per 10,000 cells measured 24 h thereafter (n = 5 +
stddev) (A) Absolute luciferase activity (RLU). Background activity of
untransfected cells was below 1000 RLU for all cell lines evaluated.
(B) Relative luciferase activity of plasmids pEPito-AFP-EGFPLuc and
pEPito-hCMV/AFP-EGFPLuc normalized to the expression activity of
pEPito-CMV-EGFPLuc in the respective cell line; insert in (B): mRNA
level of AFP mRNA normalized to the housekeeper mRNA GAPDH in
indicated cell lines (n = 2 + stddev., n.d.: not detectable).
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able levels of luciferase activity, whereas the highest levels
of luciferase activity were achieved by the CMV driven
plasmid (Figure 2A). The latter value (107 RLU/10,000
cells seeded) corresponds to a transfection efficiency based
on percentage of transgene positive cells ranging from 20-
60% using EGFP encoding, CMV driven plasmids (M.
Ogris et al., unpublished observation). The hCMV enhan-
cer increased the expression activity of the AFP driven
plasmid, although there appeared to be strong variability
between the cell lines. As there can be a large variability in
terms of transfectability of various cell lines with transfec-
tion enhancers like polyethylenimine, we normalized the
luciferase activity to the values achieved with the CMV
driven plasmid (Figure 2B). Without hCMV enhancer, the
relative activity varied between 0.05 and 0.7%. When using
the hCMV enhancer, in the hepatoma cell lines HUH7
and HepG2 the activity was boosted 18-fold and 15-fold,
achieving 6% (HUH7) resp. 12% (HepG2) activity relative
to CMV respectively. In all other cell lines, only 1-2% of
CMV activity was obtain, with the exception of MDA-MB-435 human melanoma (3.6%). The weak background
expression in all cell lines might be linked to the general
tumor characteristics of immortalized cell lines. To inves-
tigate the role of AFP expression for AFP promoter driven
transgene expression, we performed quantitative real time
analysis on endogenous AFP mRNA levels using GAPDH
as internal standard (Figure 2B, insert). Only in the report-
edly AFP positive cell lines HUH7 and HepG2 consider-
able levels of AFP mRNA were detected, whereas in all
other cell lines tested they were undetectable (below back-
ground values, i.e. not detectable after 45 rounds of PCR
amplification). Hence we conclude that the endogenous
AFP levels and the activity of the used AFP promoter
show a positive correlation, although some minor back-
ground activity is observed in AFP negative cell lines. All
data obtained so far indicate a functional usage of the
hCMV/AFP hybrid promoter element with satisfactory
specificity and sensitivity for hepatocellular carcinomas.
AFP promoter is active in a xenograft model of HUH7 in mice
To investigate the in vivo expression pattern of our
newly developed hCMV/AFP construct, we utilized the
HUH7 xenograft tumor model in immune compromised
nude mice. The EGFPLuc transgene was replaced by an
expression optimized Firefly Luciferase (oFLuc), which is
reported to achieve better in vivo signals in comparison
to the standard luciferase [21]. We also observed signifi-
cantly higher luciferase activity with oFLuc-plasmids
in vitro when compared to the normal EGFP luciferase
fusion protein (data not shown). NMRI nu/nu mice car-
ried subcutaneously implanted HUH7 tumors in the
flank, which are usually well vascularized and in
principle accessible for polycation condensed plasmids
after intravenous application [22]. As a transfection re-
agent, we used LPEI. LPEI polyplexes are known to rap-
idly aggregate in the blood stream leading to high
transgene expression in the lung [23]. Here we aimed at
investigating the de-targeting effects on lung expression
when using the AFP promoter. Polyplexes were prepared
with LPEI at an N/P ratio of 6 in a glucose buffer (HBG)
and injected via the tail vein at a dose of 2.5 mg/kg
based on pDNA (Figure 3). Two days after transfection,
animals were subject to analysis of luciferase activity by
bioluminescense imaging (BLI) and after three days lu-
ciferase activity was quantified in tumor- and tissue ly-
sates. As already observed for other luciferase encoding
plasmid with constitutive promoters, pEPito-CMV-
oFLuc based polyplexes led to predominant activity in
the lung area, whereas activity in all other areas was
rather low and not always detectable by BLI. In sharp
contrast, lung activity was strongly reduced with pEPito-
hCMV/AFP-ofLuc polyplexes, and in some animals a
weak signal was observed in the tumor area. To obtain
quantitative data on luciferase activity, animals were
Figure 3 Hepatoma specific transgene expression with pEPito-
hCMV/AFP-oFLuc in vivo. NMRI nu/nu mice bearing subcutaneous
HUH7 human hepatoma tumors were injected intravenously with
LPEI polyplexes (N/P 6) formed either with pEPito-hCMV/AFP-oFLuc
or pEPito-CMV-oFLuc at a dose of 2.5 mg/kg (n = 6 per group).
Luciferase activity (RLU/mg tissue) is shown in lysates of lung, tumor
and liver 24 h after transfection; grey bars: pEPito-CMV-oFLuc, full
bars: pEPito-hCMV/AFP-oFLuc; n = 6; * p < 0.05 (U-test, Mann–Whitney;
lung signal pEPito-hCMV/AFP-oFLuc vs. pEPito-CMV-oFLuc).
Figure 4 Transient transfection efficiency and establishment
efficiency of episomes in HEK293 and TE-671. Cells were
transfected with the indicated plasmid and Fugene 6 as transfection
reagent (A) Percentage of EGFP positive cells 48 hours after
transfection; n = 6 + stddev, ** p = 0.003 (U-test, Mann–Whitney,
pEPito-hCMV/SM22-IRES-BSD transfection HEK293 vs. TE-671)
(B) Relative colony-forming efficiency of stably selected clones
normalized to the establishment efficiency obtained with (pEPito-1-
[hCMV/EF1αP]- [EGFP-IRES-BSD]-ΔSMAR). n = 6 + stddev.
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activity measured in lysates of organs and tumor. With
the CMV driven plasmid, a considerable luciferase activ-
ity was observed in lung tissue, whereas the tumor ex-
pression was approx. eightfold lower. In sharp contrast
to the AFP driven plasmid, luciferase activity in lung was
20-fold lower, whereas the luciferase expression in
tumor was unaffected. Hence we conclude the general
functionality of the hCMV/AFP-promoter for HCC-
specific expression, both in vitro and in vivo.
Specific replication of a SM22 driven pEPito vector in a
muscle derived cell line
For tissue specific expression and replication in healthy,
adult tissue, we evaluated the human transgelin pro-
moter (synonym SM22), which is reported to be active
in muscle cells [19,20,24]. As establishment of the epi-
somes is easily detectable under selection, we applied
vectors with a blasticidin expression cassette for our ex-
periments. HEK293 were used as negative control,
whereas the muscle derived cell line TE-671 served as
the positive control. 150,000 cells were transfected with
0.25 μg DNA (using Fugene6 as transfection reagent)
and two days post transfection cells were analyzed for
the percentage of EGFP positive cells (Figure 4A) and
EGFP expression levels per EGFP positive cell (mean
fluorescence intensity, MFI, data not shown). All experi-
ments were performed by transfecting equal massamounts of vector DNA instead of equal molar ratios of
vector molecules, as we already did in our previous work
[17]. This should exclude potential side effects of stuffer
DNA, like sonicated salmon sperm DNA or any other
small plasmid DNA with varying CpG contents. In line
with our previous observations [17], pEPito-hCMV/EF1-
EGFP-IRES-BSD and pEPito-hCMV/EF1-EGFP-IRES-
BSD-ΔSMAR resulted in approx. 20% EGFP positive
cells, whereas with pEPito-hCMV/SM22-EGFP-IRES-
BSD >3% were EGFP positive. The expression level
(MFI) in HEK 293 for the hCMV/SM22 promoter con-
struct was also much weaker (MFI < 2,500, less than 8%
in direct comparison) than the levels for the hCMV/EF1
driven pEPito (>20,000). In contrast, the hCMV/SM22
construct was significantly more active in TE-671 cells,
>6% of cells were EGFP positive, corresponding to one
third of the activity of pEPito-hCMV/EF1-EGFP-IRES-
BSD (18%). The expression level (MFI) was at about 15%
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age of EGFP-positive cells observed after transfection
with pEPito-hCMV/EF1-EGFP-IRES-BSD-ΔSMAR can
be explained by the smaller size of this plasmid. A simi-
lar behaviour of the ΔSMAR construct was previously
observed in NIH3T3 cells [17]. After 14 days of selection
with blasticidin S a further FACS analysis was performed
to analyze the percentage of EGFP positive cells and
their MFI value (data not shown). Here, plasmids lacking
the SMAR-element were not able to achieve stable ex-
pression, whereas with S/MAR bearing constructs
prolonged expression was achieved. Furthermore the
SM22-promoter achieved much better expression rates
and expression levels in the TE-671 cell line than in the
HEK 293 cells when compared to the EF1α-promoter.
We omitted a ΔSMAR control vector for the tissue-
specific derivative as a logical consequence to our previ-
ous experiments. If the pEPito-hCMV/EF1-EGFP-IRES-
BSD-ΔSMAR is not able to achieve persistence, the
weaker expressing tissue-specific ΔSMAR-construct
would not perform better.
With the help of the colony forming assay the estab-
lishment rate of stable episomes and background inte-
gration values was evaluated (Figure 4B). Colony
formation units (CFU) were calculated by normalizing
the colony number to the value obtained with pEPito-
hCMV/EF1-EGFP-IRES-BSD-ΔSMAR as recently de-
scribed [17]. In HEK 293 cells, the hCMV/SM22-con-
struct resulted only very few background colonies,
whereas in TE-671 cells the same construct achieved
more colonies than the pEPito-hCMV/EF1-EGFP-IRES-
BSD-ΔSMAR. In comparison, the hCMV/SM22 driven
construct succeeded in almost 20 fold more colonies in
the TE-671 cell line than in the HEK293 cells when
compared to the hCMV/EF1-driven pEPito. Therefore
we conclude the functionality of the tissue-specific ex-
pression of the SM22 promoter in the muscle derived
TE-671 cells. The minimal expression levels of the
SM22 promoter in the HEK293 cells (Figure 4A) did not
achieve episomal retention of this plasmid. It is known,
that transcription in the SMAR is a prerequisite for epi-
somal establishment [15]. We confirmed the establish-






First number: number of rescue experiments where plasmid DNA could be
rescued without any rearrangement from the isolated chromosomal DNA.
Second number: total number of performed rescue experiments. ‵0′ indicates
that no clones could be obtained in any rescue experiment.Only the pEPito-hCMV/EF1-EGFP-IRES-BSD could be
rescued in both cell lines. The negative control, pEPito-
hCMV/EF1-EGFP-IRES-BSD-ΔSMAR did not give any
positive result, which is in line with previous experiments
[7,17]. pEPito-hCMV/SM22-EGFP-IRES-BSD could only be
rescued from genomic DNA of the stably selected TE-671
cells, indicating that this construct was maintained here as
an epsiome. On average, about hundred positive clones
were obtained from cells carrying pEPito-hCMV/
EF1-EGFP-IRES-BSD, whereas from TE-671 carrying
pEPito-hCMV/SM22-EGFP-IRES-BSD approximately 25
positive colonies were obtained. Rescued plasmid were
identified by different restriction digests. pEPito-hCMV/
EF1-EGFP-IRES-BSD-ΔSMAR did not result in any
bacterial retransformants. Taken together, the SM22-
promoter achieved better expression rates and expression
levels in the TE-671 cell line, confirming its usefulness as
a tissue-specific promoter for muscle-specific cells. For
the first time we could also show its function as a tissue-
specific promoter in a pEPI-deriviative in terms of epi-
somal establishment.
Discussion
In this manuscript we present the first description of an
episomal and tissue-specific replicating SMAR-based
vector. Combining the properties of an episomally repli-
cating, non-integrating vector system with tissue specific
promoters should in principle give a high level of bio-
safety when compared for example to integrating viral
vector systems. Nevertheless, the low efficiency of non-
viral systems can be a limiting factor. Recently, we im-
proved the existing episomal vector system pEPI by re-
placing the backbone with a CpG depleted backbone
and the promoter sequence with the strong, non-
silenced constitutive promoter for elongation factor 1α
[17]. The novel vector series termed pEPito was superior
in expression strength both in vitro and in vivo and
exhibited strongly improved establishment efficiency as
a non-integrated episome leading to long term gene ex-
pression. The aim of our first experiments was to de-
velop a pEPito vector with a strong and specific
promoter for liver and liver derived cancer cells, which
will allow the expression of high transgene levels when
used within this episomal vector construct. From our
previously published work we knew that the SMAR
element often leads to reduced transient expression
levels when compared to the ΔSMAR control (see e.g.
[17]). As tissue specific promoters are usually weaker
then strong, constitutive promoters like CMV or EF1α, a
careful selection process is necessary to identify pro-
moters with adequate specificity, but also sufficient
strength for pEPito constructs. In all experiments, trans-
fections with either constitutive or tissue specific pro-
moters were run in parallel and not using them as
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useful in other experimental setups, using a plasmid
with strong constitutive promoter can potentially inter-
fere with the transfection efficiency obtained (by com-
peting for transcription factors or at mRNA levels for
translation factors), but also in rare recombination
events, as several plasmid parts (poly A signal, bacterial
promoter, resistance cassette) are similar to the tested
plasmid. Alpha-fetoprotein is a major fetal serum pro-
tein in mammals and has it functions in ligand transport
and maintaining physiologic osmolarity [25]. The AFP
gene is transcribed at high levels in the yolk sac and fetal
liver, where the transcription declines dramatically after
birth, resulting in barely detectable AFP levels in the
liver by 4 weeks of age [26]. In hepatocellular cancer,
AFP becomes active again, a mechanism which is not
yet fully clarified yet. Silencer sequences play a critical
role in AFP promoter activity, but also regulatory re-
gions or growth related genes [27] or hepatocyte nuclear
factor 3 [28] were reported to be involved in this
process. The most used variant of the AFP-promoter
element is of murine origin including its enhancer,
which exhibits (including enhancer elements) a size
>2600 bp [18,29]. Our 600 bp AFP promoter was ampli-
fied from human genomic DNA, and together with the
hCMV enhancer element was only approximately
850 bp in size. The APO E enhancer is usually used in
combination with the hAAT promoter for liver specific
expression for factor IX in gene therapy [30,31]. Here
we omitted the hAAT promoter element to achieve
higher specificity, as the original hybrid APO E-hAAT
promoter achieved too high activity in HEK 293 cells in
pre-experiments (data not shown). The haptoglobin pro-
moter was chosen as it appeared to be very liver specific
according to TiProD [32]. Its gene product, haptoglobin,
is an abundant haemoglobin-binding protein present in
the plasma [33]. On the human hepatocellular cell line
HUH7, all three liver specific promoters resulted in a
weak transgene expression level far below 1% of the
CMV driven activity. This is in line with observations
made with other tissue specific promoters, like the mur-
ine AFP promoter [18] or muscle specific promoter ele-
ments [34]. We and other groups could show that the
hCMV enhancer element boosts transgene expression of
ubiquitous promoter both in vitro and in vivo, for ex-
ample in lung [35] or liver [36]. For this purpose, we
cloned the hCMV enhancer element upstream of the re-
spective promoters. Although the activity of all three
promoters was increased by the hCMV enhancer elem-
ent, only the hCMV/AFP combination gave satisfyingly
high levels also several days after transfection (Figure 1),
so it was used in the successive experiments. To ensure
that with the hCMV enhancer element specificity is
retained, control transfections were carried out in AFPnegative cell lines both of human and murine origin
(Figure 2). After normalizing for the activity obtained
with the CMV driven plasmid it could be observed that
the AFP positive cell lines HUH7 and HepG2 were most
susceptible to AFP mediated transgene expression,
whereas in almost all other cell lines the hCMV enhan-
cer element just boosted basal expression levels in gen-
eral (Figure 2B). QPCR studies confirmed that the HCC
cell lines HUH7 and HepG2 were positive for AFP ex-
pression levels [18,29,37,38]. Although no detectable
levels of AFP mRNA in the human melanoma cell line
MDA-MB-453, this cell line was at least to a certain ex-
tent susceptible to hCMV/AFP mediated transfection.
Approx. 3.6% of the CMV driven transgene expression
were achieved. This can be due to certain ‘leakiness’ of
the AFP promoter or the hCMV enhancer element, as it
has been observed for viral vectors with tissue or tumor
specific promoters [39]. Apparently the leakiness of our
hybrid promoter element also depends on the cell type
of tumor type. We can furthermore not exclude that the
observed basal activity of the AFP promoter might be a
indication of the tumor characteristics of all immortal-
ized cell lines.
To prove the applicability of the AFP driven pEPito
vector in vivo, nu/nu mice bearing subcutaneously im-
planted HUH7 tumors were systemically treated with
polyplexes based on LPEI. Such LPEI polyplexes usually
rapidly aggregate with blood components like erythro-
cytes and a considerable portion accumulates in the first
vascular bed encountered, namely the lung, were they
also lead to efficient transgene expression [23]. Never-
theless, transgene expression can also be found in other
organs, like liver [40], and subcutaneously implanted tu-
mors [22,41]. CMV driven transgene expression usually
peaks 12-24 h after delivery, e.g. after LPEI polyplex me-
diated delivery in lung tissue (M. Ogris et al., unpub-
lished, and [42]) or after hydrodynamic plasmid delivery
to the liver [36,43] and rapidly declines thereafter. Meas-
uring luciferase activity by BLI 48 h after delivery, a high
signal was observed in the lung area with the CMV
driven plasmid, and after 72 h there was still a consider-
able signal remaining. Luciferase activity could not be
detected with the AFP driven construct by BLI, and was
20-fold lower after 72 h in the lysates. As the tumor ex-
pression was unchanged, we apparently could improve
the in vivo specificity >20 fold. Hence we conclude that
with hCMV/AFP driven transgene expression a consid-
erable tumor specificity accompanied by strong activity
in the target tissue (HCC) can be achieved. Although
useful for proof of principle studies like presented here,
unmodified LPEI is not the ideal carrier for targeting
transgene expression to the tumor after systemic injec-
tion: In our experiment presented here, the level of lucif-
erase activity in tumors strongly varied between
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AFP driven plasmid: 3 high, 3 low). This variation in
transfectability does not correlate with size the of HUH7
tumors (ranging from 4–10 mm in diameter in this ex-
periment), as subcutaneous HUH7 tumors are already
hypervascularised at small diameter (3 mm and above, M.
Ogris et al., unpublished observations), and blood vessels
are enlarged and highly leaky [44]. We expect an influence
of functional blood flow, which can strongly vary between
tumors, but also between different time points were
polyplexes are applied. Here we rather aimed at proving
the de-targeting effect from lung. Other, better suited de-
livery systems based on LPEI developed in our group (in-
cluding shielding domains to reduce aggregation and
target domains to direct transgene expression to epider-
mal growth factor receptor overexpressing cells) are far
superior for systemic HUH7 tumor targeting, but only
show very low or absent activity in non-target organs in-
cluding lung [45,46].
Showing the principle usability of the AFP promoter
to efficiently drive transgene expression within a pEPito
vector in vitro and in vivo, but also some leakiness due
to activity on AFP negative cell lines, we examined the
tissue-specific replication of a SMAR-based vector
within a second promoter setup using similar backbone
and enhancer. For this purpose the muscle specific
SM22 promoter (human variant synonym transgelin),
was chosen. This promoter was reported to be tissue-
specific and to achieve robust transgene expression
levels. With the SM22 promoter we also expected a
higher degree of specificity and less leakiness then with
AFP, as it has also been described by other groups [39].
In vivo replication for S/MAR-based vector could so far
only be shown after sperm-mediated gene transfer [47],
but not yet with transient transfection using episomal
vectors [17,43], unless recently a selection and/or a
growth advantage was included into the episomal plas-
mids by coexpressing Bcl-2 [48]. Nevertheless, it has to
be noted that Bcl-2 overexpression itself is known to be
antiapoptotic and this gene is upregulated in tumors.
Due to these difficulties and as the SM22 promoter is
also rather weak when compared to constitutive pro-
moters and to AFP promoter (R. Haase, unpublished ob-
servations), we decided to study cell specific replication
within an in vitro setting. As the constitutive control,
the EF1α promoter was selected, which leads to long
lasting transgene expression within pEPito vectors and is
not prone to rapid silencing like the CMV immediate
early promoter element [17,36]. As expected, transfec-
tion efficiency was high both in HEK293 and TE-671
cells, and in TE-671 cells the efficiency with the ΔSMAR
construct was even higher. This is in line with our previ-
ously published data, and is due to the fact that the tran-
scription of the S/MAR sequence decreases expressionefficiency in certain cell lines [7,10,43,49]. Although at
lower efficiency then achieved with the EF1α driven vec-
tor, SM22 driven expression was significantly higher in
TE-671 cells when compared to HEK293 pointing at the
specificity of this construct (Figure 4A). The establish-
ment of stable clones with the EF1α driven pEPito was
strongly depending of the presence of the S/MAR elem-
ent in both cell lines. The SM22 only developed stable
clones in TE-671 cells at lower efficiency when com-
pared to the EF1α driven pEPito. As the transcription
into the SMAR is crucial for the establishment of epi-
somes [15], the strength of constitutive promoters influ-
ences the extent of the expression from the established
clones [17]. These facts are also known for minicircles
(J. Bode, personal communication, and ref. [50]). It
seems to be logical, that much weaker promoters than
the constitutive CMV, SV40 or EF1α promoters exhibit
lower establishing rates, which would also explain the
lower episome establishment of the muscle-specific
pEPito derivative. Background integration for S/MAR-
based vector can still not be fully excluded, but was
reported to be repressed [51]. The small amount of sta-
bly transfected HEK293 cells with the pEPito-hCMV/
SM22-construct (less than 2% of the number of the
ΔSMAR construct (Figure 4B)) showed moderate ex-
pression levels (data not shown), but as the plasmid
could not be rescued from this cell line, this indicates an
integrated status of the plasmid. Apparently the back-
ground integration is dependent of the promoter expres-
sion strength, as the promoter drives the expression and
selection unit of these vectors. We further conclude that
for every successful rescue experiment, replicated plas-
mid DNA could be accounted, as otherwise all experi-
ments would have shown positive colonies. Hence the
number of established clones of the SM22-promoter
driven construct in the TE671 cell line represent a low,
but reproducible frequency of episomal establishment.
To highlight the effect of the SMAR element, we have
normalized the data to the EF1α driven plasmid lacking
the SMAR element. The rescue experiments (Table 1)
verified the episomal status of the tissue-specific pEPito
in the respective cells, but also confirmed the correlation
between promoter strength and episomal establishment
rate [17]: with the constitutive and strong EF1α pro-
moter, about hundred positive bacterial colonies were
found per experiment, both with DNA extracts from
HEK293 and TE671 cells, whereas with SM22 driven
pEPitos this number was significantly lower (approx. 25
colonies).
Conclusions
In this study we present an episomal plasmid systems
designed for tissue specific transgene expression and
replication. The human AFP-promoter in combination
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be a valuable tissue-specific promoter for targeting hepa-
tocellular carcinomas with non-viral gene delivery sys-
tem, and tissue specific replication could be shown
in vitro with the muscle specific SM22 promoter. In
combination with appropriate delivery systems, the tis-
sue specific pEPito vector system will allow higher
tissue-specificity with less undesired side effects and is
suitable for long term transgene expression in vivo
within gene therapeutical approaches.
Methods
Vector construction
An overview of all vectors used within this study is shown
in Table 2. The pEPito-CMV-EGFPLuc, pEPito-hCMV/
EF1-EGFP-IRES-BSD and pEPito-hCMV/EF1-EGFP-IRES-
BSD-ΔSMAR were described before [17]. The human
AFP-, HPGL- and SM22-promoter were amplified by PCR
from genomic DNA of 293 HEK cells. All promoter
sequences were obtained using TiProD [32]. In general,
these sequences are the first 600 bp upstream of their nat-
ural gene product. The primers used contained PciI (5′)
and NheI (3′) restriction sites. The APOE enhancer elem-
ent (kindly provided by Mark Kay) was also amplified by
PCR. Resulting PCR-fragments were subcloned into the
pGEM-T-easy vector (Promega, Mannheim, Germany) and
respective clones further characterized by sequencing
(AGOWA, Berlin, Germany). Clones were digested with
PciI and NheI and the respective fragments cloned into
pEPito-CMV-EGFPLuc or pEPito-CMV-EGFP-IRES-BSD,
which were digested with the same enzymes, thus creating
pEPito-AFP-EGFPLuc, pEPito-APOE-EGFPLuc, pEPito-
HPGL-EGFPLuc and pEPito-SM22-EGFP-IRES-BSD. The
hCMV enhancer was amplified by PCR from pEPito-














pEPito-hCMV/SM22-EGFP-IRES-BSD hCMV/SM22sites were added (NcoI and PciI). The pEPito-
AFP-EGFPLuc, pEPito-APOE-EGFPLuc, pEPito-HPGL-
EGFPLuc and pEPito-SM22-EGFP-IRES-BSD were
digested by PciI and the amplified PCR fragment of
the hCMV enhancer was ligated into the PciI site.
The resulting constructs pEPito-hCMV/AFP-EGFPLuc,
pEPito-hCMV/APOE-EGFPLuc, pEPito-hCMV/HPGL-
EGFPLuc and pEPito-hCMV/SM22-EGFP-IRES-BSD
were sequenced to verify the correct orientation of
the hCMV enhancer. pMOD-ZGFP (Cayla Invivogen,
France) was digested with AvrII and BamHI and the frag-
ment was cloned into the vector backbone of pEPito-CMV-
EGFPLuc with NheI and BglII restricted resulting in
pEPito-CMV-ZGFP. The pEPito-CMV-ZGFP was digested
with BglII and NheI and the oFluc fragment of pV2011-
oFL (kindly provided by Dr. Brian Rabinovich, [21])
after digestion with BglII and AvrII was ligated into the
vector backbone, thus creating pEPito-CMV-oFLuc. The
same procedure was carried out for pEPito-hCMV/AFP-
EGFPLuc to generate pEPito-hCMV/AFP-oFLuc. All con-
structs were propagated in E.coli DB3.1λpir [52].
Cell culture
Human HEK293 embryonic kidney cells (ATCC CRL-
1573), TE-671 rhabdomyosarcoma (ACC 263), Cal33
tongue squamous cell carcinoma (ACC 447), SW480
colon carcinoma (ACC 313), HeLa cervix carcinoma
(ATCC CCL-2) and Neuro 2A murine neuroblastoma
(ACC 148) were cultured in DMEM (1 g glucose/l) com-
pleted with 10% FCS. U87MG human glioblastoma
(ATCC HTB-14) were grown on collagen G (Biochrom)
coated plates in DMEM/10% FCS. Human hepatocellular
carcinoma cell lines HuH7 (JCRB0403) and HepG2
(ATCC HB-8065) and human melanoma cell line MDA
MB-435 (ATCC HTB-129) were cultivated in DMEM/plasmids used in this study
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and 2 mM stable glutamine. Du145 human prostate
carcinoma line (ATCC HTB-81), LS174T human colon
carcinoma (ATCC CL-188) and NIH3T3 murine fibroblasts
were cultivated in RPMI 1640 (Biochrom) medium
supplemented with 10% FCS. U373MG glioblastoma
(ATCC HTB-17) were cultured in DMEM (5 g glucose/l)
supplemented with 20% FCS. All cultured cells were grown
at 37°C in 5% CO2 humidified atmosphere.
EGFP transfection and FACS analysis
For transfection experiments with EGFP encoding plas-
mids, 1.5 × 105 cells were seeded into a 6 well plate (BD
Falcon, USA) 24 hours prior to the experiment and there-
after transfected using 0.25 μg vector DNA per well using
Fugene6 (Roche, Germany) as transfection reagent
according to the manufacturer’s instructions. Two days
(48 hours) post transfection cells were trypsinized,
resuspended in phosphate buffered saline (PBS) (Invitrogen,
Germany), and divided into two aliquots. One aliquot was
analyzed for EGFP expression using a FACS Canto II flow
cytometer (Becton Dickinson, Germany). The other aliquot
was cultured in the presence of blasticidin (7 μg/ml) (PAA,
Austria). After 12 days of selection, stably selected (mixed-
clone) cells were again analyzed for EGFP expression.
Luciferase assay
Cells were seeded 24 h before transfection and the cell
medium was exchanged for fresh growth medium (with
serum) directly prior transfection. Polyplexes were formed
in HEPES-buffered saline (HBS, 20 mM HEPES, 150 mM
NaCl, pH 7.1) with pDNA and the transfection reagent
HDO solution at a C/P (conjugate to plasmid, w/w) ratio of
2 at a final pDNA concentration of 20 μg/ml followed by
20 minutes incubation at room temperature. After 4 h trans-
fection the solution was exchanged for fresh cell medium.
For measuring luciferase activity, cells were trypsinised,
10,000 cells lysed in 0.5x lysis buffer (Promega, Mannheim,
Germany) and analyzed by luciferase-assay [53]. Background
activity of untransfected cells was <1,000 RLU.
Xenograft nude mice model, in vivo transfection/
transduction and in vivo bioluminescence
In vivo experiments were carried out in principle as de-
scribed [22]. In brief, six week old female Rj:NMRI nu/
nu mice (Janvier, Le Genest-Saint-Isle, France) received
5 x 106 HUH7 cells resuspended in 100 μl PBS subcuta-
neously into the flank. After reaching a tumor size of
8 mm (2–3 weeks after inoculation) LPEI based
polyplexes were formed at N/P 6 (molar ratio of nitro-
gen in LPEI to phosphate groups in plasmid DNA) with
a final concentration of 200 μg/mL pDNA in HEPES-
buffered glucose (HBG, 20 mM HEPES, 5% glucose w/v,
pH 7.1) and injected intravenously at a DNA dose of2.5 mg/kg. One, two and three days after injection ani-
mals were monitored by in vivo bioluminescence im-
aging (BLI) after intraperitoneal injection of 6 mg Na-
luciferin (Promega, Mannheim, Germany) dissolved in
100 μl PBS. BLI was performed with an IVIS lumina sys-
tem (CaliperLS, Mannheim, Germany). At day three
after polyplex application, animals were euthanized, indi-
cated organs and tumors explanted, lysed and the lucif-
erase activity determined from an aliquot of the lysate.
Animals were housed in individually vented cages with
a 12 h light/dark cycle and unlimited access to food and
water. All animal experiments were approved by the
local ethics committee (Regierung von Oberbayern) and
carried out according to the German law for protection
of animals (Tierschutzgesetz).
Colony-forming assay
For colony forming assays, transfected cells were split from
6 well plates into 75 cm2 flasks at 48 hours post transfec-
tion. Splitting of cells was performed at serial dilutions
(1:1, 1:10, and 1:100). After a total of 12 days of selection
with blasticidin colonies were fixed with 4% paraformalde-
hyde (Sigma, Germany) in PBS, counterstained with
methylene blue (Sigma, Germany) and counted.
Isolation of genomic DNA from cell lines
For isolation of genomic DNA from transfected and stably
selected cell lines, cells were trypsinized, resuspended in
PBS, and counted. Genomic DNA was isolated from 107
cells using the QiaAMP DNA Mini Kit (Qiagen, Germany)
according to the manufacturer’s instructions.
Quantitative real-time PCR
Total RNA was isolated using miRCURY RNA Isolation Kit
(Exiqon, Vedbaek, Denmark) and transcribed with the
Transcriptor High Fidelity cDNA Synthesis Kit (Roche,
Mannheim, Germany) according to manufacturer’s proto-
cols. Quantitative real-time PCR was performed using UPL
Probes (Roche, Mannheim, Germany) and LightCycler 480
Probes Master (Roche, Mannheim, Germany) on a
LightCycler 480 system (Roche, Mannheim, Germany). The
following primer sequences were used for the human alpha-
fetoprotein (NM_001134.1): AFP left: tgtactgcagagataag
tttagctgac and AFP right: tccttgtaagtggcttcttgaac. AFP
mRNA levels were normalized to GAPDH as control using
Human GAPDH Reference Gene Assay (Roche, Mannheim,
Germany). Experiments were done in triplicates and the
obtained average CT values were normalized to control as
ΔCT. Expression changes in the target gene were analyzed
as ratio AFP/GAPDH (2-ΔCT).
Bacterial rescue experiments
To verify the episomal status of pEPito vectors within
transfected and stably selected mammalian cell lines,
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ical transformation of 10 μl isolated genomic DNA
(approximately 500 ng) into chemical competent E.coli
DB3.1λpir [52]. Transformed bacteria were selected on
LB-plates containing ampicillin. Plasmid DNA was pre-
pared from transformed bacteria using the Qiaprep Spin
Miniprep Kit (Qiagen, Germany) according to the manu-
facturer’s instructions. The integrity of the rescued plas-
mids was checked by restriction analysis and gel
electrophoresis. For rescue experiments of cell culture
materials, chromosomal DNA of stably selected mixed
clones was isolated three times independently and
transformed into bacteria. Resulting bacterial clones
were analyzed for the integrity of their isolated plasmids
by three different restriction digests with XhoI (dual cut-
ter), PciI and NheI (both single cutters) and BglII and
BamHI (both single cutters). Only if the rescued and
retransformed plasmids showed the same digestion pat-
tern as the original plasmid, the rescue was counted as
successful, In case no colonies could be obtained from
the initial transformations, this procedure was repeated
twice. For a complete negative rescue the DNA was iso-
lated three times and each DNA isolation was
transformed three times into the bacterial host strain.
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